Lyrica

Lyrica. It is a medication primarily used to treat neuropathic pain, fibromyalgia, and as an adjunctive therapy for partial-onset seizures in adults. Developed as a successor to gabapentin, it is also approved for the management of generalized anxiety disorder in some countries. The drug is classified as an anticonvulsant and is known for its binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system.

Medical uses

Lyrica is approved by the U.S. Food and Drug Administration for the treatment of postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, neuropathic pain associated with spinal cord injury, and partial-onset seizures. In the European Union, it also holds marketing authorization for generalized anxiety disorder. Clinical trials, such as those published in the New England Journal of Medicine, have demonstrated its efficacy in reducing pain scores and improving patient function in conditions like postherpetic neuralgia. It is often prescribed when first-line treatments like amitriptyline or duloxetine are ineffective or not tolerated. The National Institute for Health and Care Excellence provides guidelines for its use within the National Health Service.

Adverse effects

Common adverse effects include dizziness, somnolence, peripheral edema, and weight gain, with the latter being a significant concern for long-term management. More serious risks include angioedema, hypersensitivity reactions, and an increased potential for suicidal thoughts or behaviors, a warning mandated by the FDA for many anticonvulsants. Abrupt discontinuation can lead to withdrawal symptoms such as insomnia, headache, and nausea, similar to those seen with benzodiazepines. The Medicines and Healthcare products Regulatory Agency monitors post-marketing safety data, and cases of visual field defects have been reported to organizations like the World Health Organization's pharmacovigilance database.

Pharmacology

The mechanism of action involves high-affinity binding to the alpha-2-delta subunit of voltage-gated calcium channels, which are widely distributed in the cerebral cortex, amygdala, and hippocampus. This binding reduces the influx of calcium ions into presynaptic neurons, thereby decreasing the release of several neurotransmitters, including glutamate, noradrenaline, and substance P. Unlike gabapentin, it exhibits linear pharmacokinetics with high bioavailability. It undergoes negligible metabolism in humans and is excreted renally, primarily unchanged, which necessitates dose adjustment in patients with impaired renal function as defined by the Cockcroft-Gault equation.

History

Lyrica was discovered and developed by the pharmaceutical company Pfizer. Its active pharmaceutical ingredient, pregabalin, was designed as a more potent and predictable analog of gabapentin. The drug received its first approval from the FDA in December 2004 for neuropathic pain and adjunctive epilepsy therapy. Subsequent approvals for fibromyalgia and other indications followed in numerous countries, including those within the European Medicines Agency jurisdiction. Patent expirations, such as the loss of exclusivity in the United States in 2019, led to the introduction of generic versions manufactured by companies like Teva Pharmaceutical Industries.

Society and culture

Lyrica has been the subject of significant media attention and regulatory scrutiny due to its potential for misuse and dependence, particularly in regions like the United Kingdom and Australia. It is classified as a Schedule V controlled substance in the United States under the Controlled Substances Act. High-profile cases, such as those investigated by the BBC, have highlighted its street value and association with polydrug use. The drug has also been involved in numerous product liability lawsuits against Pfizer, and its global sales once represented a major revenue stream for the company, often discussed in reports by Bloomberg L.P..

Category:Anticonvulsants Category:Pfiler drugs Category:World Health Organization essential medicines